Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer

BACKGROUND: Low-molecular-weight heparin (LMWH) is the standard treatment for venous thromboembolism (VTE) in patients with active cancer. However, use of factor Xa inhibitors, such as rivaroxaban, is increasing on the basis of limited clinical evidence. The present single-center study compared the...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jang Ho, Oh, Yeon-Mok, Lee, Sang-Do, Lee, Jae Seung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543062/
https://www.ncbi.nlm.nih.gov/pubmed/31144482
http://dx.doi.org/10.3346/jkms.2019.34.e160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543062/
https://www.ncbi.nlm.nih.gov/pubmed/31144482
http://dx.doi.org/10.3346/jkms.2019.34.e160

Ejemplares similares